PATENT ABSTRACTS

instability and the presence of impurities. An ini- tial Factor VIIi containing aqueous solution such as blood plasma is purified by subjecting a Factor VIII containing aqueous migrant solu- tion to continuous flow electrophoresis wherein flow takes place in an annular separation cham- ber and is stabilized by means of an angular velocity gradient; and collecting a separated Fac- tor Vlll component. In order to separate the Factor VIII from albumin and firbrinogen, while obtaining good recoveries of Factor VIII (e.g. - 60o/o), the migrant solution is prepared by pre- cipitating Factor VIII from the initial solution using ethanol, and removing and redissolving the precipitate in an aqueous medium and ad- justing the pH to be within the range of 7.5 to 8.6, preferably 8.3 to 8.6.

405

4465665

D E T O X I F I E D E. C O L I N E U R O T O X I N , P R E P A R A T I O N

T H E R E O F A N D I M M U N O L O G I C A L

P R E P A R A T I O N S C O N T A I N I N G IT

Lucia Dobrescu. Brussels, Belgium asmgned to Smithkline-Rit

Detoxified but still immunogenic E. coli neurotoxin is prepared by bringing E. coli neurotoxin into contact with gluturaldehyde in mild operative conditions, the reaction being stopped where no more than 90°0 of the neurotoxin are inactivated. The obtained detox- ified neurotoxin is valuable for immunizing piglets against oedema disease.

4465622

M E T H O D F O R P U R I F Y I N G I N T E R F E R O N

Masahiro Nobuhara, Kiyoshi Yamaguchi, Ei Mochida, Saitama, Japan assigned to Mochida Pharmaceutical Co Ltd

A method for purifying interferon having anti- cancer effects or anti-viral effects, wherein highly purified interferon can be easily obtained by a single operation in a recovery of about 100?../O. In this method, interferon ts obtained by specifically adsorbing interferon onto a carrier containing acrylonitrile polymer and eluting the adsorbed interferon with an appropriate buffer.

4465624

P R O C E S S F O R P R O D U C I N G E R Y T H R O P O I E T I N

Hideo Chiba, Ryuzo Sasaki, Masatsugu Ueda, Uji, Japan assigned to Snow Brand Milk Pro- ducts Co Ltd

Disclosed herein is a process for producing erythropoietin, comprising bringing a material containing erythropoietin into contact with an adsorbent having a monoclonal anti- erythropoietin antibody, adsorbing erythropoietin on the adsorbent, and eluting the absorbed erythropoietin from the adsorbent.

4465670

M E T H O D F O R T H E T R E A T M E N T O F S Y S T E M I C L U P U S

E R Y T H E M A T O S U S A N D P R I M A R Y

G L O M E R U L O N E P H R I T I S A N D A G E N T T H E R E F O R

Tetsuzo Sugisaki, Shinichi Morisue. Urawa. Japan assigned to Dainippon Pharmaceutical Co Ltd

A method for the treatment of diseases such as systemic lupus erythematosus and primary glomerulonephritis by administering a gamma- globulin having Fc fragment to patients suf- feting from such diseases in parenteral route (particularly intravenously) and a preparation useful for the treatment. The gamma-globulin having Fc fragment is usually used in the form of a preparation thereof in admixture with a con- ventional liquid carrier on diluent for injection, including a plasmin-treated human gamma- globulin preparation, a sulfonated human gamma-globulin preparation and a polyethylene glycol-treated human gamma-globulin prepara- tion.

4465776

M O N O C L O N A L A N T I B O D I E S T O V I T A M I N 116 A N D

I M M U N O A S S A Y M E T H O D

John A Cidlowski, Dac Viceps-Madore assigned to Research Corporation